Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03240809 · ClinicalTrials.gov registry record · Phase 4
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
A Phase 4 study of Psoriasis, sponsored by Bausch Health Americas.
- Active
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
- 5
- Study locations
NCT03240809 is a Phase 4 study of Psoriasis that is active but no longer recruiting, run by Bausch Health Americas. The registered enrollment target is 2 participants, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT03240809, a Phase 4 study of Psoriasis, is active but no longer recruiting, sponsored by Bausch Health Americas.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
- 5
- Study locations
Study Summary
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Conditions Studied
Interventions
- BIOLOGICAL Brodalumab
Study Locations (5)
Florida
- Bausch Site 002 - Miami
- Bausch Site 004 - Miami
Nevada
- Bausch Site 005 - Henderson
- Bausch Site 001 - Las Vegas
California
- Bausch Site 003 - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-01-24 |
| Est. Completion | 2029-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03240809
The ClinicalTrials.gov registry entry for NCT03240809 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 489-participant average among 125 other Psoriasis trials with a reported enrollment target (100% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Brodalumab is the first listed.
NCT03240809 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, Nevada, California.
Frequently Asked Questions
What is clinical trial NCT03240809 about?
NCT03240809 is a clinical study titled "An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects". An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
What is the current status of trial NCT03240809?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2020-01-24. Estimated completion is 2029-06.
What conditions does trial NCT03240809 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03240809?
The interventions under investigation include: Brodalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03240809?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03240809 being conducted?
This trial has 5 study locations across California, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.